Yelp Inc. (NYSE: YELP) missed both revenue and profit estimates for the fourth quarter of 2019 when it reported results on Thursday. The stock, which dropped during after-hours trading, has still not recovered and was down 9% in early trade on Friday.
Revenues grew 10% year-over-year to $269 million but analysts were looking for $273 million. EPS fell to $0.24, missing estimates of $0.26. The revenue growth was lower than the company expected due to larger seasonal reductions by small and medium-sized business customers. Profits were hurt by higher income taxes during the quarter.
Looking at the full year, in 2019, the company managed to grow ad clicks for advertisers by 34% and reduce average cost per click by 18% through an efficient advertising auction system as well as ad targeting.
In 2020, Yelp is looking to roll out new types of advertising such as themed ads and the company is also working on developing its customization capabilities so that advertisers can mould their campaigns based on their needs. These efforts are expected to help drive retention gains in the year ahead.
Yelp also sees a massive opportunity to grow its multi-location business going forward. The company is looking to include the multi-billion dollar digital advertising opportunity in the services category.
The company is revamping its sales channel mix and reducing its dependence on sales headcount to drive revenue growth. Yelp is also working on improving its margins by driving growth in its multi-location and self-serve channels, which are the most profitable.
Yelp expects revenues to grow 8-10% in the first quarter of 2020 and 10-12% in fiscal year 2020 versus the respective comparable periods.
The stock has dropped 17% in the past one year and 9% in the past one month. Two analyst firms have downgraded the stock following the fourth quarter results.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
